Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

17 Oct 2025

Thymic health found to predict immunotherapy success in cancer patients

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international study reported at ESMO 2025.

16 Oct 2025

Housing support programs tied to improved cancer detection among seniors

A new study led by researchers from the Johns Hopkins Bloomberg School of Public Health found that older adults receiving federal housing assistance were on average diagnosed at earlier stages with three common cancers-colon, breast, and non-small cell lung-compared to peer cancer patients who were not receiving assistance.

8 Oct 2025

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

Bio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD oncology kits in Europe

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix' CE-IVD Droplex™ digital PCR oncology testing kits throughout Europe.

3 Oct 2025

Stereotactic radiotherapy offers long-term survival outcomes comparable to surgery for NSCLC patients

A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC). Patients in the study who received radiation also reported fewer side effects after treatment.

30 Sep 2025

Tissue-mimicking hydrogels drive cell reprogramming via matrix remodeling

The mechanical properties of tissue matrix are crucial for maintaining cell health and function. With aging, tissue matrix loses its mechanical integrity and exhibits altered biophysical properties, which are closely associated with various diseases including neurodegenerative diseases and cancers.

30 Sep 2025

Stereotactic body radiation therapy and surgery show similar outcomes for early lung cancer

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body radiation therapy (SBRT) and surgery achieved similar survival outcomes at 10-year follow-up for patients with early-stage non-small cell lung cancer, with radiation offering quality-of-life benefits.

26 Sep 2025

Machine learning models can predict urgent care needs for patients with non–small cell lung cancer

A new study published in JCO Clinical Cancer Informatics demonstrates that machine learning models incorporating patient-reported outcomes and wearable sensor data can predict which patients with non–small cell lung cancer are most at risk of needing urgent care during treatment.

16 Sep 2025

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Lung tumors don't just evade the immune system. They reshape it at its source. Researchers from the Icahn School of Medicine at Mount Sinai and collaborators report in the September 10 online issue of Nature that tumors rewire immune cells in the bone marrow before they even reach the cancer, suggesting a new target to enhance the durability of current immunotherapy

10 Sep 2025

New AI model can identify treatments that reverse disease states in cells

In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells.

10 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

9 Sep 2025

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

9 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Small Cell Lung Cancer News and Research

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Thymic health found to predict immunotherapy success in cancer patients

Housing support programs tied to improved cancer detection among seniors

NCCN enhances widely used breast cancer guidelines with advanced digital features

Bio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD oncology kits in Europe

Stereotactic radiotherapy offers long-term survival outcomes comparable to surgery for NSCLC patients

Tissue-mimicking hydrogels drive cell reprogramming via matrix remodeling

Stereotactic body radiation therapy and surgery show similar outcomes for early lung cancer

Machine learning models can predict urgent care needs for patients with non–small cell lung cancer

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

New AI model can identify treatments that reverse disease states in cells

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News